Emyria starts EMD-RX5 clinical development program

Latest News

Emyria (ASX:EMD) has announced that participant recruitment, screening and consenting has commenced for the EMD-RX5 clinical development program.

EMD-RX5 is an ultra-pure, highly bioavailable cannabidiol (CBD) capsule. Emyria says it has the potential to become a registered treatment for multiple indications.

EMD-RX5 is the company’s first, proprietary cannabinoid-based medical treatment.

Emyria said it is initially seeking registration of EMD-RX5 with the TGA as a low-dose, Schedule 3, 'over-the-counter' CBD treatment for the symptoms of psychological distress. 

It said a pivotal Phase 3 clinical trial protocol required for registration has already been developed and, pending successful ethics approval, is expected to commence immediately following the Phase 1 trial.

Emyria’s managing director Dr Michael Winlo said, “ Emyria’s first registration program is aimed at developing an over-the-counter, Schedule 3 treatment targeting the symptoms of psychological distress - a growing global mental health concern affecting about 15% of all adults in Australia alone and which currently has no over-the-counter treatment available.

"EMD-RX5 also meets the strict requirements for product purity with both the TGA in Australia and the FDA in the USA, and as such, we believe EMD-RX5 has the potential to become a registered treatment in additional markets and for multiple clinical indications.

"Since the EMD-RX5 clinical development program was developed with insights from Emyria’s growing Real-World Data asset, the Company is able to move quickly from Phase 1 through to a Pivotal Phase 3 clinical trial. Uniquely amongst cannabidiol registration programs,

Emyria’s Phase 1 clinical trial will directly compare the bioavailability of EMD-RX5’s proprietary formulation to the only successfully registered and reimbursed CBD oil in the global market to date, Epidyolex.

"I look forward to providing further updates on EMD-RX5 and our expanding cannabinoid portfolio.”